T. Rowe Price Associates
HRTX icon

T. Rowe Price Associates’s Heron Therapeutics HRTX Stock Holding History

T. Rowe Price Associates’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90K Buy
111,504
+34,866
+45% +$40.4K ﹤0.01% 3018
2025
Q4 		$100K Hold
76,638
– – ﹤0.01% 2947
2025
Q3 		$97K Sell
76,638
-2,805,039
-97% -$4.45M ﹤0.01% 2931
2025
Q2 		$5.97M Sell
2,881,677
-122,999
-4% -$251K ﹤0.01% 1229
2025
Q1 		$6.61M Buy
3,004,676
+2,958,497
+6,407% +$5.74M ﹤0.01% 1195
2024
Q4 		$71K Buy
46,179
+8,684
+23% +$14.1K ﹤0.01% 2886
2024
Q3 		$75K Hold
37,495
– – ﹤0.01% 2872
2024
Q2 		$132K Buy
37,495
+7,573
+25% +$23.3K ﹤0.01% 2700
2024
Q1 		$83K Buy
29,922
+3,991
+15% +$10K ﹤0.01% 2809
2023
Q4 		$45K Buy
25,931
+5,127
+25% +$5.64K ﹤0.01% 2821
2023
Q3 		$22K Sell
20,804
-35,800
-63% -$51K ﹤0.01% 2849
2023
Q2 		$66K Buy
56,604
+2,047
+4% +$3.65K ﹤0.01% 2768
2023
Q1 		$83K Buy
54,557
+6,320
+13% +$15.8K ﹤0.01% 2716
2022
Q4 		$121K Buy
48,237
+2,118
+5% +$6.82K ﹤0.01% 2677
2022
Q3 		$195K Buy
46,119
+14,351
+45% +$56.2K ﹤0.01% 2555
2022
Q2 		$89K Sell
31,768
-1,460
-4% -$5.86K ﹤0.01% 2779
2022
Q1 		$190K Buy
33,228
+3,233
+11% +$23.7K ﹤0.01% 2727
2021
Q4 		$274K Sell
29,995
-23,400
-44% -$239K ﹤0.01% 2630
2021
Q3 		$571K Buy
53,395
+2,800
+6% +$34.1K ﹤0.01% 2316
2021
Q2 		$785K Sell
50,595
-6,826
-12% -$109K ﹤0.01% 2172
2021
Q1 		$931K Sell
57,421
-13,077
-19% -$233K ﹤0.01% 2092
2020
Q4 		$1.49M Sell
70,498
-1,347
-2% -$23.4K ﹤0.01% 1742
2020
Q3 		$1.06M Buy
71,845
+8,730
+14% +$136K ﹤0.01% 1768
2020
Q2 		$928K Buy
63,115
+1,271
+2% +$20.9K ﹤0.01% 1819
2020
Q1 		$726K Buy
61,844
+18,874
+44% +$355K ﹤0.01% 1832
2019
Q4 		$1.01M Sell
42,970
-17,055
-28% -$377K ﹤0.01% 1880
2019
Q3 		$1.11M Buy
60,025
+12,572
+26% +$231K ﹤0.01% 1778
2019
Q2 		$882K Buy
47,453
+322
+0.7% +$6.43K ﹤0.01% 1893
2019
Q1 		$1.15M Buy
47,131
+383
+0.8% +$10K ﹤0.01% 1784
2018
Q4 		$1.21M Buy
46,748
+12,725
+37% +$350K ﹤0.01% 1724
2018
Q3 		$1.08M Buy
34,023
+25,320
+291% +$943K ﹤0.01% 1859
2018
Q2 		$338K Buy
+8,703
New +$277K ﹤0.01% 2308
2017
Q4 		– Sell
-15,327
Closed -$248K – 2587
2017
Q3 		$248K Buy
15,327
+4,900
+47% +$76.9K ﹤0.01% 2336
2017
Q2 		$144K Buy
+10,427
New +$151K ﹤0.01% 2440

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

T. Rowe Price Associates's HRTX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Heron Therapeutics (HRTX) stake by 45% in Q1 2026, buying an estimated $40.4K and bringing the position to 111,504 shares worth $90K. The position accounts for ﹤0.01% of the portfolio, ranked #3018.

T. Rowe Price Associates first reported a position in HRTX in Q2 2017 and has held it in 34 quarters since. The position peaked at $6.61M in Q1 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • T. Rowe Price Associates held 111,504 shares of Heron Therapeutics worth $90K as of Q1 2026.
  • T. Rowe Price Associates bought 34,866 Heron Therapeutics shares in Q1 2026, an estimated $40.4K.
  • Heron Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3018 holding.
  • T. Rowe Price Associates first reported a position in Heron Therapeutics in Q2 2017 and has held it in 34 quarters since.
  • T. Rowe Price Associates's Heron Therapeutics position peaked at $6.61M in Q1 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.